IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene ABL1 Ensembl ENSG00000097007 Chromosome 9 Start 132578987 End 132752883
Description Proto-oncogene tyrosine-protein kinase ABL1 (EC 2.7.10.2)(Abelson murine leukemia viral oncogene homolog 1)(c-ABL)(p150) [Source:UniProtKB/Swiss-Prot;Acc:P00519]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 76
     Entrez Gene : 25
     UCSC : uc004bzw.2
     GeneCards : 76
     RefSeq : NM_005157
     CCDS : CCDS35165.1
     Uniprot : P00519
     Interpro : P00519
     OMIM : 189980
     GeneTests : ABL1
     CGAP : ABL1
     PMID : 1857987

< Top >


Somatic Mutaions        (help)
Lung cancer Adenocarcinoma Squamous Cell Carcinoma
Unique Mutated Samples % Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
3 1.33 225 2 1.03 195 0 0.00 7
Sample datas
Sample Name Histology Subtype DNA Mutation Protein Mutation Mutation Description Zygosity Genomic Co-ordinates NCBI36 Pubmed
16646 AD c.2417C>T p.P806L Substitution - Missense Heterozygous 9:132749915-13274991518948947
16770 AD c.2196G>T p.R732S Substitution - Missense Heterozygous 9:132749694-13274969418948947

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1635_at  -0.41  2.78e-5  1.31e-4  -0.62  1.90e-6  1.12e-5
 HG_U95  1636_g_at  0.13  5.86e-2  1.05e-1  0.02  8.50e-1  8.94e-1
 HG_U95  1656_s_at  0.39  4.97e-2  9.17e-2  0.15  5.77e-1  6.71e-1
 HG_U95  2040_s_at  0.12  1.14e-1  1.83e-1  0.11  2.93e-1  3.95e-1
 HG_U95  2041_i_at  0.05  7.82e-1  8.43e-1  -0.54  1.11e-1  1.79e-1
 HG_U95  39730_at  -0.14  4.35e-2  8.20e-2  -0.32  5.90e-4  1.95e-3
 HG_U133A  202123_s_at  0.00  9.22e-1  9.34e-1  -1.88  6.52e-68  2.03e-67
 HG_U133_Plus2  202123_s_at  0.10  2.58e-1  3.43e-1  0.43  1.68e-5  4.18e-5
 Stanford  7014  0.38  1.59e-1  3.36e-1  -0.29  2.68e-1  5.07e-1
 Stanford  9868  0.47  3.80e-2  1.39e-1  0.25  4.11e-1  6.44e-1
 Agilent_HS_21.6K  17405  -0.10  2.39e-5  3.61e-4  -0.09  1.12e-3  5.92e-3

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  202123_s_at  0.07  6.68e-1  9.63e-1  0.12  2.93e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1635_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1636_g_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1656_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 2040_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 2041_i_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 39730_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 202123_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 202123_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 7014    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 9868    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 17405    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
abl1 bladder cancer Using only the 5 markers most strongly associated with bladder cancer selected by logistic regression analysis, namely ABL1, IFNa, D9S12, MJD58 and D18S364, LOH test sensitivity slightly decreased to 90%. 11832713 Human
abl1 cancer We conclude that D-FISH reliably detects standard Ph chromosomes as well as its variant translocations and accurately quantifies BCR/ABL1 rearrangements prior and during cancer treatment as well as in the phase of remission, in daily routine tumor cytogen 11904740 Human
abl1 tumor We conclude that D-FISH reliably detects standard Ph chromosomes as well as its variant translocations and accurately quantifies BCR/ABL1 rearrangements prior and during cancer treatment as well as in the phase of remission, in daily routine tumor cytogen 11904740 Human
c-abl myeloid leukemia The response of myeloid leukemia cells to treatment with 1-beta-D-arabinofuranosylcytosine (ara-C) includes activation of the c-Abl protein tyrosine kinase and the stress-activated protein kinase (SAPK). 12021410 Human
c-abl human colon carcinoma Our results were further confirmed by studies performed on genetically defined mutants, i.e. mouse embryo fibroblasts derived from knock-out animals for c-Abl or p53, as well as human colon carcinoma cell lines deficient in MLH1. 12023887 Human
v-abl metastasis Ectopic expression of SOCS-1 abolished proliferation mediated by a constitutively active form of the KIT receptor, TEL-JAK2, and v-ABL, and reduced metastasis from BCR-ABL transformed cells. 12080466 Human
c-abl hepatoma Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B. 11374898 Human
c-abl human hepatoma In human hepatoma Hep3B cells, SORBS1 was partly dissociated from the insulin receptor complex and bound to c-Abl protein upon insulin stimulation. 11374898 Human
c-abl thyroid cancer Interestingly, one of the targets of STI571, namely the c-Abl tyrosine kinase, is activated by HGF and is recruited at the migrating edge of thyroid cancer cells. 11439348 Human
c-abl thyroid cancer These data suggests that c-Abl and/or STI571-inhibited tyrosine kinases can negatively regulate the Met receptor to restrain the motile response in thyroid cancer cells. 11439348 Human
c-abl myelodysplastic syndromes In contrast, WBCs from healthy donors, acute myelogenous leukemias, acute lymphocytic leukemias, and myelodysplastic syndromes were unmethylated at the c-abl Pa promoter locus. 10779450 Human
c-abl oral squamous-cell carcinomas c-Abl expression in oral squamous cell carcinomas. c-Abl is proto-oncogene product. c-Abl has roles in signal transduction, cell cycle regulation, and inhibition of apoptosis. 10889926 Human
c-abl oral squamous-cell carcinomas In the present study, biopsy specimens from 44 patients with oral squamous cell carcinomas were subjected to immunohistochemistry, and the expression levels of c-Abl were correlated with clinicopathological features. 10889926 Human
c-abl monocytic leukemia Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. 10022809 Human
p150 squamous-cell carcinoma p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. 10096238 Human
p150 esophageal squamous-cell carcinoma To investigate p150, a recently cloned protein, and its prognostic value in esophageal squamous-cell carcinoma, 100 samples were analyzed immunohistochemically and 30 fresh samples by the immunoblot method. 10096238 Human
p150 tumor metastases In addition, patients with high p150 expression had significantly fewer tumor metastases (local or distant, p < 0.005). 10096238 Human
p150 cervical carcinoma This somehow unexpected result may, however, be typical for squamous carcinoma, since in human cervical carcinoma, another squamous carcinoma, the p150 values were reported to rise early in all tumors, to stay high in patients with longer survival as well 10096238 Human
p150 squamous carcinoma This somehow unexpected result may, however, be typical for squamous carcinoma, since in human cervical carcinoma, another squamous carcinoma, the p150 values were reported to rise early in all tumors, to stay high in patients with longer survival as well 10096238 Human
p150 lymph-node metastasis In addition, patients with regional lymph-node metastasis and high p150 expression survived longer than those with regional lymph-node metastasis and lower p150 expression (p < 0.0066). 10096238 Human
p150 squamous-cell carcinoma The results suggest that p150 may be a new biomarker for squamous-cell carcinoma of the esophagus, with specific prognostic value. 10096238 Human
c-abl myeloid leukaemias Preliminary molecular studies on two chromosome 2 encoded genes, c-abl and beta 2M, in radiation-induced murine myeloid leukaemias. 3276637 Human
c-abl embryonal carcinoma Expression of c-src and c-abl in embryonal carcinoma cells and adult mouse tissues. 2458954 Mouse
c-abl multiple myeloma Eight reactive lymphatic tissues, 166 cases of non-Hodgkin lymphomas (NHL) and 11 cases of multiple myeloma were investigated for expression of the c-abl protein using the poly-clonal anti-abl antibody 4411 and an indirect peroxidase technique. 3049401 Human
c-abl non-hodgkin lymphomas Eight reactive lymphatic tissues, 166 cases of non-Hodgkin lymphomas (NHL) and 11 cases of multiple myeloma were investigated for expression of the c-abl protein using the poly-clonal anti-abl antibody 4411 and an indirect peroxidase technique. 3049401 Human
c-abl multiple myeloma When the clinical status of 78 patients with NHL and 11 patients with multiple myeloma was related to c-abl expression, c-abl-positivity was mostly confined to patients in advanced tumor stages [p less than 0.001 (NHL)]. 3049401 Human
c-abl human renal-cell carcinomas We have analyzed the expression of 12 protooncogenes, c-Ha-ras, c-Ki-ras, N-ras, c-myc, N-myc, c-fos, c-abl, c-fes, c-fms, c-raf, c-erbB-1, and c-erbB-2, in tissues of human renal cell carcinomas and in adjacent normal kidneys. 2460228 Human
c-abl thyroid carcinomas We suggest that amplification of gene(s) located at chromosome 9, other than the C-ABL, may play a significant role in anaplastic evolution of thyroid carcinomas. 9595037 Human
c-abl human myeloid leukemia Immunoprecipitation experiments revealed that CK2alpha is associated with normal c-Abl in mouse NIH3T3 fibroblasts and with the Bcr-Abl fusion protein in K562 human myeloid leukemia cells. 9671309 Human
c-abl chronic leukemias The excessive proliferation of the myeloid marrow compartment in Philadelphia chromosome (Ph)-positive acute and chronic leukemias has been largely attributed to a hyperactive and autonomously acting hybrid tyrosine kinase BCR-ABL, a product of the fusion 9676840 Human
v-abl pre-b-cell leukemia Abelson murine leukemia virus encodes the related oncogene product, v-Abl, and also causes pre-B-cell leukemia. 9050373 Human
v-abl plasma cell tumors Overexpression of v-abl uniquely cooperates with c-myc dysregulation in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphocytic interference. 8690515 Human
c-abl acute leukemia A novel oncogene containing ABL is formed by the (9;12) translocation which fuses part of the ets-family member TEL to c-ABL in patients with acute leukemia. 8808688 Human
abl1 ewing sarcoma Comparing results obtained for the EWSR1/FLI1 and ABL1/BCR genes in samples of patients suffering from Ewing sarcoma or chronic myelogenous leukaemia, it can be concluded that the mean positions of the fusion genes are determined by the final structure of 12522555 Human
c-abl myeloid leukemia Herein, we show that STI571, an inhibitor of Bcr-Abl in chronic myelogenous leukemia, blocks activation of c-Abl in the response of mouse embryo fibroblasts and human U-937 myeloid leukemia cells to hydrogen peroxide (H(2)O(2)). 12527798 Mouse
v-abl myelodysplasia Deregulated expression of v-abl and BCR/abl genes has been associated with myeloproliferative syndromes and myelodysplasia, both of which can progress to acute leukemia. 7565761 Human
c-abl human myeloid leukemia KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. 8609723 Human
c-abl philadelphia positive acute lymphoblastic leukemia bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. 3465378 Human
c-abl hematologic malignancy The c-abl locus is translocated from chromosome 9 to chromosome 22 in chronic myelogenous leukemia (CML), creating the Philadelphia chromosome (22q-, Ph1), one of the most consistent chromosomal abnormalities found in human hematologic malignancy. 2578837 Human
v-abl murine leukemia The mouse c-abl gene, part of the sequence of which was captured in Moloney murine leukemia virus to generate the transforming gene (v-abl) of the Abelson murine leukemia virus, has been isolated and characterized. 6319018 Mouse
c-abl murine leukemia The mouse c-abl gene, part of the sequence of which was captured in Moloney murine leukemia virus to generate the transforming gene (v-abl) of the Abelson murine leukemia virus, has been isolated and characterized. 6319018 Mouse
c-abl burkitt lymphoma Two notable examples are that of the t(9;22) translocation of chronic myelogenous leukemia (CML), causing the transfer of the oncogene c-abl from chromosome 9 to chromosome 22, and that of the t(8;14) translocation of Burkitt lymphoma, causing the transfe 6383040 Human
v-abl abelson murine leukaemia In the present study, sequences encoding the tyrosine phosphorylation acceptor sites of the Abelson murine leukaemia virus oncogene, v-abl, and its human cellular homologue, c-abl, have been identified and their nucleic acid sequences determined. 6191223 others
c-abl abelson murine leukaemia In the present study, sequences encoding the tyrosine phosphorylation acceptor sites of the Abelson murine leukaemia virus oncogene, v-abl, and its human cellular homologue, c-abl, have been identified and their nucleic acid sequences determined. 6191223 others
v-abl blast crisis Here we show that human cellular sequences (c-abl) homologous to the transforming sequences of the mouse Abelson leukemia virus (v-abl) are amplified some 4- to 8-fold in K-562, a Philadelphia chromosome-positive cell line derived from a patient with chro 6308652 Human
c-abl blast crisis Here we show that human cellular sequences (c-abl) homologous to the transforming sequences of the mouse Abelson leukemia virus (v-abl) are amplified some 4- to 8-fold in K-562, a Philadelphia chromosome-positive cell line derived from a patient with chro 6308652 Human
c-abl burkitt's lymphoma A remarkable concordance between the chromosomal location of human cellular oncogenes and the breakpoints involved in acquired chromosomal translocations is becoming apparent in various cancers: the oncogenes c-mos, c-myc and c-abl are located at the brea 6312328 Human
c-abl acute myeloblastic leukaemia A remarkable concordance between the chromosomal location of human cellular oncogenes and the breakpoints involved in acquired chromosomal translocations is becoming apparent in various cancers: the oncogenes c-mos, c-myc and c-abl are located at the brea 6312328 Human
v-abl lymphosarcoma The v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) is known to efficiently transform NIH/3T3 fibroblasts in vitro and to cause an acute lymphosarcoma in susceptible murine hosts. 2440107 Mouse
v-abl murine leukemia Moloney murine leukemia virus-induced myeloid tumors in adult BALB/c mice: requirement of c-myb activation but lack of v-abl involvement. 2824810 Mouse
v-abl t-cell lymphomas Since Moloney virus is thought to induce mostly T-cell lymphomas, we have carried out studies to investigate this alteration of disease specificity and to determine whether v-abl played an obligatory role in the development of these tumors. 2824810 Human
c-abl hematologic malignancies C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies. 3456250 Human
c-abl erythroblastic leukemia Enhanced transcription of the cellular homolog (c-abl) of the transforming sequence of Abelson murine leukemia virus was observed in K3D, which was one of the cloned cell lines of 7,12-dimethylbenz[a]anthracene-induced rat erythroblastic leukemia. 3456563 Rat
v-abl mouse erythroleukemia v-abl activates embryonic globin gene expression in mouse erythroleukemia cells. 3008148 Mouse
c-abl mouse erythroleukemia To test directly if the protein products of the translocated c-abl protooncogene can activate embryonic globin gene expression, we transfected the v-abl oncogene (which shares the property of autophosphorylation with the translocated c-abl protooncogene) 3008148 Mouse
v-abl mouse erythroleukemia To test directly if the protein products of the translocated c-abl protooncogene can activate embryonic globin gene expression, we transfected the v-abl oncogene (which shares the property of autophosphorylation with the translocated c-abl protooncogene) 3008148 Mouse
c-abl renal-cell tumors Renal cell tumors were screened for expression of the cellular oncogenes c-abl, c-fes, c-fms, c-myc, c-ras, and c-sis in dot blot hybridization analysis. 3018974 Human
c-abl metastatic melanomas Analysis of the expression of 13 additional cellular protooncogenes revealed either no detectable levels (c-fms, c-abl, v-src, c-erb A1, c-erb B, v-mos, TGF beta, and c-myb) or unaltered expression levels (cH-ras, N-ras, c-fos, and c-sis) in normal human 2121834 Human
c-abl multiple myeloma Philadelphia positive multiple myeloma is a very rare event and, so far, no molecular data about the involvement of the BCR and C-ABL genes are available. 2232886 Human
c-abl serous carcinoma Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. 12910520 Human
c-abl ovarian carcinomas Immunohistochemical expression of c-ABL, PDGFR-beta, and c-KIT was evaluated in ovarian carcinomas to determine whether treatment with imatinib mesylate might be feasible. 12910520 Human
c-abl serous carcinomas METHODS: The expression of c-ABL, c-KIT, and PDGFR-beta in tumors was evaluated by immunohistochemical analysis of 52 ovarian serous carcinomas, including 21 low-grade (well differentiated) and 31 high-grade (poorly differentiated) tumors. 12910520 Human
c-abl serous carcinomas Overall, c-ABL was expressed in 71% of serous carcinomas. c-ABL was expressed more frequently in the low-grade serous carcinomas (81%) compared with the high-grade serous carcinomas (65%). 12910520 Human
c-abl human ovarian carcinomas Expression of p73 and c-Abl proteins in human ovarian carcinomas. 12928725 Human
c-abl ovarian cancer However, the role of p73 and c-Abl in ovarian cancer is not well-defined. 12928725 Human
c-abl benign ovarian tumors We investigated immunohistochemical expressions of p73 and c-Abl in 64 ovarian carcinomas, 13 borderline and 14 benign ovarian tumors to elucidate their clinicopathological relevances. 12928725 Human
c-abl ovarian carcinomas We investigated immunohistochemical expressions of p73 and c-Abl in 64 ovarian carcinomas, 13 borderline and 14 benign ovarian tumors to elucidate their clinicopathological relevances. 12928725 Human
c-abl benign ovarian tumors Of the malignant, borderline, and benign ovarian tumors, respectively, 33 (51%), 10 (77%) and 13 (93%) had negative or low p73 expression, 31 (48%), 3 (23%) and 1 (7%) had high p73 expression, 23 (36%), 5 (38%) and 10 (71%) had negative or low c-Abl expre 12928725 Human
c-abl ovarian carcinomas A high p73 or c-Abl expression was significantly associated with ovarian carcinomas as compared to benign tumors (p=0.003 and p=0.03 respectively). 12928725 Human
c-abl acute erythroid leukemias Of these, transcripts coding for c-abl and c-src were absent in blast cells of acute erythroid leukemias. 2915575 Human
c-abl non-hodgkin lymphomas We investigated the practical value of antisense RNA/mRNA in situ hybridization for the detection of low level expression of the c-abl oncogene in non-Hodgkin lymphomas. 2651801 Human
v-abl malignant non-hodgkin lymphomas When the optimized method was applied to the v-abl-transformed NIH 3T3-, the K 562 CML blast cell line and to nine cases of lowly malignant non-Hodgkin lymphomas it semiquantitatively discriminated the varying amounts of v-abl, bcr/c-abl and c-abl mRNA ex 2651801 Human
c-abl malignant non-hodgkin lymphomas When the optimized method was applied to the v-abl-transformed NIH 3T3-, the K 562 CML blast cell line and to nine cases of lowly malignant non-Hodgkin lymphomas it semiquantitatively discriminated the varying amounts of v-abl, bcr/c-abl and c-abl mRNA ex 2651801 Human
c-abl carcinoma Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion. 12955086 Human
v-abl lung carcinomas Seven lung carcinomas were grafted on nude mice and continuously propagated as in vivo models on which the amplification of 9 oncogenes (N-myc, v-erb A, v-abl, v-sis, c-myc, c-myb, v-Ha-ras, c-Kiras, and v-scr) was studied by Southern blot hybridization. 2568771 Mouse
c-abl plasmacytoma Mutants and fusion products of the c-abl gene were used to define some of the molecular requirements for rapid plasmacytoma (PC) and pre-B-lymphoma induction in pristane-treated N-myc transgenic BALB/c mice. 8014009 Human
c-abl anaplastic thyroid carcinomas To establish a molecular targeting therapy for anaplastic thyroid carcinomas, we studied the effect of the specific tyrosine kinase inhibitor, STI571, on anaplastic thyroid cancer cell lines highly expressing c-ABL ARO (mutated p53) and FRO (undetectable 12679488 Human
c-abl anaplastic thyroid cancer To establish a molecular targeting therapy for anaplastic thyroid carcinomas, we studied the effect of the specific tyrosine kinase inhibitor, STI571, on anaplastic thyroid cancer cell lines highly expressing c-ABL ARO (mutated p53) and FRO (undetectable 12679488 Human
c-abl papillary thyroid cancer In contrast, the growth of papillary thyroid cancer cell lines that harbor wild-type p53 and have low levels of c-ABL was not affected by STI571. 12679488 Human
c-abl undifferentiated thyroid carcinomas Taken together, these results suggest that selective suppression of c-ABL activity by STI571 may represent a potential anticancer strategy for p53-mutated undifferentiated thyroid carcinomas. 12679488 Human
c-abl cervical cancer Bak and c-abl were found to be potential genes that may play important roles in signaling apoptosis in cervical cancer cells following radiation induction. 12684676 Human
v-abl thymic lymphoma BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. 8396667 Human
v-abl murine leukemia To determine whether other lymphocytes of this strain were susceptible to transformation, and to identify genes that can collaborate with v-abl in tumorigenesis, E mu-v-abl 40 mice were subjected to insertional mutagenesis by neonatal infection with Molon 8406991 Human
c-abl burkitt's lymphoma Rearrangements of c-myc and c-abl genes in tumour cells in Burkitt's lymphoma. 8408711 Human
c-abl burkitt's lymphoma Rearrangements of oncogenes c-myc and c-abl were detected by non-radioactive hybridisation in a case of Burkitt's lymphoma/leukaemia. 8408711 Human
c-abl burkitt's lymphoma The physiopathological implications of the rearranged c-abl gene are unknown, this being the first case, as for as is known, of Burkitt's lymphoma/leukaemia with a rearranged c-abl gene. 8408711 Human
c-abl childhood leukaemia A different mechanism of oncogene activation in a leukaemia specific chromosomal abnormality is found for CML, where c-abl sequences are fused into the bcr locus, or in the t(4; 11) of acute childhood leukaemia involving the recently identified ALL-1 gene 8142618 Human
c-abl chronic phase cml These findings (i) confirm previous observations showing a lineage specific requirement of c-abl function in normal hematopoiesis, and (ii) suggest that the residual c-abl expression has a role in chronic phase CML hematopoiesis, as its inhibition impairs 1736009 Human
v-abl myeloid leukemia Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression of v-abl tyrosine kinase. 1617678 Mouse
c-abl thyroid cancer We have also found that c-Abl tyrosine kinase, an activator of p73, is excluded from the nucleus of p73alpha-positive thyroid cancer cells; whereas c-Abl undergoes nuclear-cytoplasmic shuttling in normal thyroid and p73-negative thyroid cancer cells. 12716888 Human
v-abl murine leukemia A series of recombinant retroviral genomes was generated by cotransformation of NIH 3T3 cells with a mixture of cloned DNAs: a proviral copy of the wild-type Moloney murine leukemia virus, and Moloney-based vectors containing defective copies of the chick 1895387 Human
v-abl human leukaemia Here we report that RNA homologous to the oncogene (v-abl) of Abelson murine leukaemia virus (A-MLV) is expressed in a unique human leukaemia in a fashion different from that of other human tissues and tumours. 7121605 Human
abl1 myeloproliferative disorders Detection of methylated ABL1 promoter in philadelphia-negative myeloproliferative disorders. 12667992 Human
abl1 t-cell acute lymphoblastic leukemia Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. 15361874 Human
abl1 t-all Here we describe the extrachromosomal (episomal) amplification of ABL1 in 5 of 90 (5.6%) individuals with T-ALL, an aberration that is not detectable by conventional cytogenetics. 15361874 Human
abl1 t-all We detected the NUP214-ABL1 transcript in five individuals with the ABL1 amplification, in 5 of 85 (5.8%) additional individuals with T-ALL and in 3 of 22 T-ALL cell lines. 15361874 Human
abl1 fab m2 We report on a patient with Ph-positive AML (FAB M2, major BCR/ABL1 mRNA transcript, b2a2), who is in sustained complete cytogenetic and molecular remission for 15 months. 15136244 Human
abl1 enteropathy-type t-cell lymphoma Amplification of NOTCH1 and ABL1 gene loci is a frequent aberration in enteropathy-type T-cell lymphoma. 15756589 Human
c-abl ph1 chromosome negative chronic myelogenous leukemia The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia. 3217110 Human
c-abl thymomas H-, K-, N-ras, c-myc, c-myb, and c-abl genes were consistently expressed in thymomas, as well as in normal, age-matched thymus. 2475843 Human
c-abl ph- cml It was investigated whether Ph- CML with clinical and morphological features indicating true CML would always have bcr rearrangements, as the relocation of c-abl from 9q34 into the breakpoint cluster region on 22q11 is considered a crucial event in the pa 2197265 Human
c-abl ph1-positive leukemias [c-abl gene and bcr-abl fused gene in Ph1-positive leukemias] 2255098 Human
c-abl hematopoietic cell proliferation We used an antisense strategy to study the relationship between c-abl expression and hematopoietic cell proliferation and differentiation. 7579442 Human
c-abl ewing tumour RESULTS: Flow cytometric and RT-PCR analyses in a panel of eight Ewing tumour cell lines demonstrated expression of several imatinib mesylate-sensitive tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-ABL and c-ARG. 12172985 Human
c-abl necrosis ROS-induced apoptosis and necrosis involves activation of the cytoplasmic c-Abl tyrosine kinase and thereby signaling to mitochondria. 12527798 Mouse
c-abl ovarian serous carcinoma Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. 12910520 Human
c-abl ovarian serous carcinomas METHODS: The expression of c-ABL, c-KIT, and PDGFR-beta in tumors was evaluated by immunohistochemical analysis of 52 ovarian serous carcinomas, including 21 low-grade (well differentiated) and 31 high-grade (poorly differentiated) tumors. 12910520 Human
c-abl benign tumors A high p73 or c-Abl expression was significantly associated with ovarian carcinomas as compared to benign tumors (p=0.003 and p=0.03 respectively). 12928725 Human
c-abl breast cancer Coupling of RAFTK/Pyk2 kinase with c-Abl and their role in the migration of breast cancer cells. 14654952 Human
c-abl cholangiocarcinoma Interestingly, cholangiocarcinoma cells do not express detectable PDGFR, c-Abl or c-Kit, which are protein kinases known to be directly inhibited by STI-571. 15566522 Human
c-abl gastrointestinal stromal tumors Imatinib mesylate is a small molecule inhibitor of the c-Abl, platelet-derived growth factor (PDGF) receptor and c-Kit tyrosine kinases that is approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointesti 15727903 Human
c-abl gastrointestinal stromal tumors Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors. 15735062 Human
p150 gastric carcinoma p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. 15382063 Human
p150 gastric carcinomas To clarify the significance of p150 expression, 102 gastric carcinomas were immunohistochemically investigated and 14 fresh samples of the cancer were analyzed with the immunoblot method. 15382063 Human
p150 gastric cancers Eighty-six out of 102 (85%) gastric cancers stained positively for p150. 15382063 Human
p150 gastric cancer Statistical analysis revealed a close association between p150 overexpression and the clinicopathologic parameters of gastric cancer. 15382063 Human
p150 metastases Furthermore, high p150 expression was more frequently seen in tumors at early invasive stages (p < 0.005), in tumors without metastases (both local and distant, p < 0.005) and in early TNM stages (p < 0.005) in general. 15382063 Human
p150 esophagus carcinoma As we have found for cervix and esophagus carcinoma, when tumors progress to high malignancy and metastasis, p150 begins to regress and then breaks down. 15382063 Human
p150 metastasis As we have found for cervix and esophagus carcinoma, when tumors progress to high malignancy and metastasis, p150 begins to regress and then breaks down. 15382063 Human
p150 cervix carcinoma The results suggest that p150 may be a new early tumor marker for gastric carcinoma similar to that for esophagus and cervix carcinoma. 15382063 Human
p150 gastric carcinoma The results suggest that p150 may be a new early tumor marker for gastric carcinoma similar to that for esophagus and cervix carcinoma. 15382063 Human
v-abl myeloid tumors Moloney murine leukemia virus-induced myeloid tumors in adult BALB/c mice: requirement of c-myb activation but lack of v-abl involvement. 2824810 Mouse
v-abl lymphoid neoplasm Although the v-abl gene can provoke several types of lymphoid neoplasm, mice of a transgenic strain (E mu-v-abl 40) in which lymphocytes are targeted for expression of v-abl by a linked immunoglobulin enhancer (E mu) spontaneously develop only plasmacytom 8406991 Human
v-abl plasma cell tumors In this report, we describe induction of plasma cell tumors in littermate control and Bcl-X(L) transgenic mice with a retrovirus expressing v-Abl and c-Myc. 15725478 Mouse
the abl gene mrd We therefore propose to use the ABL gene as CG for RQ-PCR-based diagnosis and MRD detection in leukemic patients. 14562124 Human
v-abl sarcomas The v-abl oncogene of the Abelson murine leukemia virus exhibits a narrow tissue tropism for transformation, almost exclusively forming pre-B-cell tumors, while the v-src oncogene can induce a variety of sarcomas and other tumors. 8361756 Human
c-abl embryonal carcinoma (ec) Protooncogenes expressed in murine embryonal carcinoma (EC) cells or their differentiated daughter cells include more or less ubiquitously expressed protooncogenes such as c-myc, c-K-ras, and c-abl, as well as c-onc genes with a very restricted expression 2647482 Mouse
c-abl acute promyelocytic leukemia (apl) The Lipocortin II cDNA probe detects at least four independently segregating loci which map to human chromosome regions 4q21-q31.1, 9pter-q34 proximal to c-abl, 10q proximal to 10q24 and 15q21-q22 proximal to the 15q22 translocation breakpoint characteris 2969496 Human
c-abl nhl Eight reactive lymphatic tissues, 166 cases of non-Hodgkin lymphomas (NHL) and 11 cases of multiple myeloma were investigated for expression of the c-abl protein using the poly-clonal anti-abl antibody 4411 and an indirect peroxidase technique. 3049401 Human
c-abl nhl When the clinical status of 78 patients with NHL and 11 patients with multiple myeloma was related to c-abl expression, c-abl-positivity was mostly confined to patients in advanced tumor stages [p less than 0.001 (NHL)]. 3049401 Human
c-abl erythroleukemia Four protooncogenes (c-fos, c-abl, N-ras, and c-raf) were expressed at low levels in both steps of erythroleukemia. c-fos and c-abl RNAs were barely detectable in normal erythroid cells. 3164254 Human
c-abl osteosarcomas The expression of 7 protooncogenes (c-sis, c-abl, c-mos, c-bas, c-Ki-ras, c-fos, c-myc) was examined in transplants and established cell lines from spontaneous and radiation-induced murine osteosarcomas. 3459717 Mouse
c-abl osteosarcomas Three osteosarcomas showed over-expression of c-abl (TVK, DOS, Os5), c-bas (DOS, Os5 and V893) and c-fos (TVK, DOS, Os5), and 4 osteosarcomas showed over-expression of c-Ki-ras (TVK, DOS, Os5, Os16) and c-myc (TVK, DOS, TV, Os5). 3459717 Mouse
c-abl carcinoma of breast [Oncogenes and oncogene products--possibilities and significance of their detection] Diagnosis- and/or prognosis-related alterations of (proto) oncogenes may be detected in neuroblastoma (N-myc), carcinoma of breast and ovary (HER2/neu), NHL (c-myc, bcl-2 1708608 Human
c-abl nhl [Oncogenes and oncogene products--possibilities and significance of their detection] Diagnosis- and/or prognosis-related alterations of (proto) oncogenes may be detected in neuroblastoma (N-myc), carcinoma of breast and ovary (HER2/neu), NHL (c-myc, bcl-2 1708608 Human
c-abl embryonal carcinoma (ec) We have studied the expression of c-src and c-abl proto-oncogenes in early mouse development using embryonal carcinoma (EC) cells as a model system, and compared this to the expression pattern in adult tissues. 2458954 Mouse
c-abl neurofibroma Genetic or pharmacological inhibition of c-abl reverses fibroblast proliferation and collagen synthesis to wild-type levels.These studies identify a novel molecular target to inhibit neurofibroma formation. 16835260 Human
the abl gene adult acute lymphoblastic leukemia The ABL gene on chromosome band 9q34 is a proto-oncogene and is the well-known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality 15282669 Human
the abl gene burkitt's lymphoma The discovery that some of these genes were located at the breakpoints of chromosome rearrangements in human malignancies, such as the MYC gene in Burkitt's lymphoma and the ABL gene in chronic myeloid leukemia (CML) has suggested that chromosome abn 12836614 Human
c-abl multiple myeloma Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. 17308109 Human
c-abl renal cell tumors Renal cell tumors were screened for expression of the cellular oncogenes c-abl, c-fes, c-fms, c-myc, c-ras, and c-sis in dot blot hybridization analysis. 3018974 Human
c-abl human renal cell carcinomas We have analyzed the expression of 12 protooncogenes, c-Ha-ras, c-Ki-ras, N-ras, c-myc, N-myc, c-fos, c-abl, c-fes, c-fms, c-raf, c-erbB-1, and c-erbB-2, in tissues of human renal cell carcinomas and in adjacent normal kidneys. 2460228 Human
v-abl sch Our results indicate that SCH 51344 inhibits the ability of v-abl, v-mos, H-ras, v-raf, and mutant active MAP kinase kinase-transformed NIH 3T3 cells to grow in soft agar. 7585559 Human
c-abl plasmacytoma Mutants and fusion products of the c-abl gene were used to define some of the molecular requirements for rapid plasmacytoma (PC) and pre-B-lymphoma induction in pristane-treated N-myc transgenic BALB/c mice. 8014009 Human
c-abl pheochromocytoma The interaction of c-Abl with TrkA was also observed in differentiated pheochromocytoma PC12 cells. 10679771 Human
c-abl chondrosarcomas METHODS: Sections from 16 chondrosarcomas were stained immunohistochemically using a polyclonal antibody to the c-Abl/Bcr-Abl oncoprotein. 10748867 Human
c-abl colon cancer Overexpression of p47(phox) increased apoptosis in colon cancer cell lines independent of p53 and mismatch-repair competency. p47(phox) was found to interact with the c-Abl adapter Abl interactor-1 (ABI-1), and p47(phox) coprecipitated with both ABI-1 and 12681507 Human
c-abl colon cancer Ectopic expression of p47(phox) in colon cancer cells increased oxidant production with phosphorylation and activation of nuclear c-Abl and consequent apoptosis. 12681507 Human
c-abl necrosis THRP expression induces PC12 cell death; (2). under these experimental conditions the form of cell death is predominantly necrosis although cell cycle arrest may also occur; (3). the effect of THRP on cell viability is not modulated by c-Abl tyrosine kina 12698219 Human
c-abl mds BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) 12767088 Human
c-abl mpd BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) 12767088 Human
c-abl myelodysplastic syndrome BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) 12767088 Human
c-abl myeloproliferative disorders BACKGROUND: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) 12767088 Human
c-abl invasive carcinoma Here, we report that cytoplasmic c-Abl tyrosine kinase determines whether a cell invades the ECM or commits suicide. c-Abl phosphorylates the cytoskeleton-associated adaptor protein, Crk, at tyrosine 221, causing disassociation of Crk from the Crk-associa 12955086 Human
c-abl metastasis Together, these data illustrate that c-Abl prevents aberrant motility and survival through Crk 221 phosphorylation and modulation of Crk/CAS complexes, and that deregulation of this pathway contributes to cell metastasis. 12955086 Human
c-abl gastrointestinal stromal tumors (gists) Imatinib also inhibits the c-abl, platelet-derived growth factor (PDGF) receptor, abl-related gene (ARG) and stem-cell factor (SCF) receptor tyrosine kinases, and has been used clinically to inhibit the growth of malignant cells in patients with CML and g 15637141 Human
c-abl carcinoma Using human carcinoma cells with gain and loss of MUC1 function, we show that nuclear targeting of c-Abl by DNA damage is abrogated by a MUC1-dependent mechanism. 16888623 Human
abl1 mpd We performed fluorescent in situ hybridization (FISH) with the recently developed BCR/ABL1 D-FISH probe (QBIOgene, Illkirch, F) on cultured bone marrow and peripheral blood cells of 71 patients with CML, ALL, AML, and myeloproliferative disorder (MPD). 11904740 Human
abl1 minimal residual disease We reached the following conclusions: (1) FISH is the only technique that promptly identifies T-cell ALL patients with ABL1 amplification, (2) quick identification with FISH is fundamental in the clinic because this T-cell ALL subset is imatinib sensitive 16213363 Human
c-abl oral squamous cell carcinomas c-Abl expression in oral squamous cell carcinomas. c-Abl is proto-oncogene product. c-Abl has roles in signal transduction, cell cycle regulation, and inhibition of apoptosis. 10889926 Human
c-abl oral squamous cell carcinomas In the present study, biopsy specimens from 44 patients with oral squamous cell carcinomas were subjected to immunohistochemistry, and the expression levels of c-Abl were correlated with clinicopathological features. 10889926 Human
v-abl nsclc Expression of seven common endogenous control genes (glyceraldehyde-3-phosphate dehydrogenase (GAPDH), v-abl Abelson murine leukaemia viral oncogene homologue 1, beta-2-microglobulin, hypoxanthin phosphoribosyltransferase 1 (HPRT1), phosphoglycerate kinas 16319328 Human
c-abl breast cancer Kinase co-expression was also seen in tumor subgroups and was particularly significant in breast cancer where IGF-R protein was expressed together with PDGF-R and c-Abl (P = 0.003 and P = 0.004, respectively), and in colon cancer where PDGF-R was correlat 15613459 Human
c-abl colon cancer Kinase co-expression was also seen in tumor subgroups and was particularly significant in breast cancer where IGF-R protein was expressed together with PDGF-R and c-Abl (P = 0.003 and P = 0.004, respectively), and in colon cancer where PDGF-R was correlat 15613459 Human
c-abl glioblastoma Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy. 16205964 Human
c-abl glioblastomas When ranked by their discriminating power to separate 37 glioblastomas (high-grade gliomas) from 45 lower-grade gliomas, the following 12 proteins were identified as the most powerful discriminators: IBalpha, EGFRpTyr845, AKTpThr308, phosphatidylinositol 16619307 Human
c-abl gliomas When ranked by their discriminating power to separate 37 glioblastomas (high-grade gliomas) from 45 lower-grade gliomas, the following 12 proteins were identified as the most powerful discriminators: IBalpha, EGFRpTyr845, AKTpThr308, phosphatidylinositol 16619307 Human
c-abl metastatic melanoma Methods: Tumor biopsies from 13 patients with metastatic melanoma were screened by immunohistochemistry for PTK [c-kit, C-abl, Abl-related gene (ARG), PDGF receptor-alpha (PDGFR-alpha) and PDGFR-beta] expression before and after being treated with Gleevec 16630177 Human
c-abl human hepatoblastoma Nuclear Accumulations of p53 and Mdm2 Are Accompanied by Reductions in c-Abl and p300 in Zinc-Depleted Human Hepatoblastoma Cells. 16636310 Human
c-abl breast cancer Furthermore, activation of Abl kinases promotes breast cancer cell invasion, as treatment of cells with the Abl kinase inhibitor, STI571, or silencing c-Abl and Arg expression with RNA interference dramatically inhibits Matrigel invasion. 16740702 Human
abl1 adult b-cell acute lymphoblastic leukemia The t(9;22)(q34;q11) translocation occurs in chronic myeloid leukemia (CML) and adult B-cell acute lymphoblastic leukemia (ALL), leading to fusion of BCR to ABL1 and constitutive activation of ABL1 tyrosine kinase activity. 16518848 Human
abl1 adult acute myeloid leukemias NPM1 gene mutations are the most frequent genetic lesion in the 60% of adult acute myeloid leukemias (AMLs) with normal karyotype and no evidence of typical fusion genes (BCR/ABL1, PML/RARA, AML1/ETO, CBFB/MYH11, DEK/CAN). 16645213 Human
the abl protein m1 leukemia In vitro derived myeloid cell lines from relapse M1 leukemia cells of patient 1 also expressed the P185BCR-ABL protein. 2685476 Human
v-abl primary tumor Southern blot analysis with a v-abl specific probe not only demonstrated that primary tumors are clonal, but also that the pattern of A-MuLV provirus integration is quite stable in primary tumor cells, as well as in their derived cell lines and clones. 2554549 Human
v-abl primary tumors Southern blot analysis with a v-abl specific probe not only demonstrated that primary tumors are clonal, but also that the pattern of A-MuLV provirus integration is quite stable in primary tumor cells, as well as in their derived cell lines and clones. 2554549 Human
v-abl tumorigenesis Also, our results suggest that a threshold amount of the v-abl protein product is necessary for in vitro transformation, and this level of expression may be different from the level selected during in vivo tumorigenesis. 2838788 Human
v-abl primary tumor Hybridization of DNAs from these tumors with v-abl, immunoglobulin mu, and T-cell antigen receptor beta-chain probes confirmed the T-lymphoid, polyclonal nature of the primary tumor cells. 2874233 Human
v-abl fibrosarcomas These results imply an important function for alpha TGF and the EGF receptor in the establishment of the v-abl-induced fibrosarcomas. 3023060 Mouse
v-abl systemic mastocytosis An immature v-abl-transformed mast cell line (V3-MC) was derived from a mouse that developed systemic mastocytosis after transplantation of v-abl-infected bone marrow cells. 7648391 Human
v-abl mec 2,5-MeC inhibited the morphological transformation and the activation of v-abl tyrosine kinase by the temperature shift (39 degrees C to 33 degrees C) more effectively than erbstatin. 8013266 Human
v-abl lymphomagenesis Insertion near the c-myc, N-myc or pim-I gene was observed in 42% of the induced tumors, indicating that each of these genes may collaborate with v-abl in lymphomagenesis. 8406991 Human
v-abl lymphomagenesis Thus, high expression of v-abl may not be required for Moloney-induced T lymphomagenesis. 8406991 Human
v-abl lymphomagenesis c-fos is not essential for v-abl-induced lymphomagenesis. 8521413 Human
v-abl bladder carcinoma In antiproliferative assays, the compound was more than 30-100-fold more potent in inhibiting growth of v-abl-transformed PB-3c cells and v-sis-transformed BALB/c 3T3 cells relative to inhibition of EGF-dependent BALB/MK cells, interleukin-3-dependent FDC 8548747 Human
v-abl mastocytosis After the adoptive transfer of V3 mast cells into BALB/c mice, v-abl-immortalized mast cells with mono- and multi-lobular nuclei were detected in the lymph nodes and other tissues of the mastocytosis mice that expressed c-kit, mMCP-5, mMCP-6, and mMC-CPA. 9207474 Human
v-abl leukemogenesis Our data show that the expression of the v-abl oncogene in a primary lymphoid-myeloid hemopoietic stem cell directly initiates leukemogenesis by stimulating factor-independent growth. 1996361 Human
v-abl solid tumors DNA from the cells of the solid tumors was analyzed by Southern blotting using v-abl and actin probes. 2115719 Human
v-abl lymphomas The protein-tyrosine kinase activity and hybrid structure of P210bcr/abl are similar to the oncogene product of the Abelson murine leukemia virus, P160gag/v-abl, which induces acute lymphomas. 2406902 others
the abl gene leukemogenesis This cell line, MY, expressing a novel variant P180BCR/ABL protein with a deletion of the a2 exon of the ABL gene, may be useful for elucidating the pathophysiology of this fusion protein and for studying ETV6-related leukemogenesis and t(2;3), as well as 9790503 Human
c-abl carcinogenesis The abundance of c-src transcripts was unchanged throughout carcinogenesis; c-abl and c-mos transcripts were not detected in either preneoplastic or neoplastic livers. 2581126 Human
c-abl sclc The protooncogenes c-fes, c-fos, and c-erbB were expressed very weakly and the transcripts of the oncogenes c-mos, c-sis, c-erbA, c-src, and c-abl were not observed in any of the 12 SCLC-cell lines. 2824028 Human
c-abl hcc No significant differences in mRNA levels of c-fos, N-myc, N-ras, Ha-ras, c-erbA, c-erbB and c-abl were observed among the HCC, cirrhosis and normal-chronic hepatitis groups. 2843721 Human
c-abl fibrosarcoma Hardy-Zuckerman 2 feline sarcoma virus (HZ2-FeSV), isolated from a multicentric feline fibrosarcoma is a replication-defective acute transforming feline retrovirus which originated by transduction of feline c-abl sequences with feline leukemia virus (FeLV 3029415 Human
c-abl erythroleukemia Four protooncogenes (c-fos, c-abl, N-ras, and c-raf) were expressed at low levels in both steps of erythroleukemia. c-fos and c-abl RNAs were barely detectable in normal erythroid cells. 3164254 Human
c-abl leukemogenesis The amplification and rearrangement of c-abl imply the activation of proto-oncogene in leukemogenesis. 3219975 Human
c-abl osteosarcomas The expression of 7 protooncogenes (c-sis, c-abl, c-mos, c-bas, c-Ki-ras, c-fos, c-myc) was examined in transplants and established cell lines from spontaneous and radiation-induced murine osteosarcomas. 3459717 Mouse
c-abl osteosarcomas Three osteosarcomas showed over-expression of c-abl (TVK, DOS, Os5), c-bas (DOS, Os5 and V893) and c-fos (TVK, DOS, Os5), and 4 osteosarcomas showed over-expression of c-Ki-ras (TVK, DOS, Os5, Os16) and c-myc (TVK, DOS, TV, Os5). 3459717 Mouse
c-abl ph negative cml Data suggest that co-operation between the overexpressed c-abl and c-myb oncogenes is causally related to Ph-negative bcr-negative CML. 8182928 Human
c-abl neuroblastomas Role of c-abl oncogene in chronic myeloid leukemia (CML), bcl-2, in lymphomas, N-myc in neuroblastomas and retinoblastoma (Rb) gene in retinoblastomas is well understood and used in designing proper therapeutic approaches. 8244494 Human
c-abl leukemogenesis This study indicates that molecular events other than bcr rearrangement and c-abl juxtaposition were involved in leukemogenesis in this patient. 8330271 Human
c-abl gbm Hypermethylation of N33, ER, HIC1, P16, P15 and c-abl were found in 61%, 59%, 60%, 5%, 2% and 0% of GBM respectively. 9671399 Human
c-abl neuroblastoma [Oncogenes and oncogene products--possibilities and significance of their detection] Diagnosis- and/or prognosis-related alterations of (proto) oncogenes may be detected in neuroblastoma (N-myc), carcinoma of breast and ovary (HER2/neu), NHL (c-myc, bcl-2 1708608 Human
c-abl oncogenes Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine. 2425967 Human
abl1 malignant transformation Alterations of ABL1 by chromosomal rearrangement or viral transduction can lead to malignant transformation. 9500553 Human
c-abl glioblastomas Statistical analysis did not reveal any correlation between expression of the TKs and patient survival.We show here for the first time in a large series of glioblastomas that PDGFR-alpha, -beta, c-kit, c-abl and arg expression is immunohistochemically det 16205964 Human
c-abl glioblastoma The goal of our study was to assess systematically immunohistochemical expression of the major TKs targeted by imatinib mesylate in glioblastoma, as expression of these factors could be used to select patients for imatinib mesylate therapy.In a cohort of 16205964 Human
c-abl mammary tumors Phosphorylation of c-Kit, PDGFRs and c-Abl is inhibited in Int3 transgenic mammary tumors by Gleevec. 16878155 Mouse
c-abl tumorigenesis To examine the signaling mechanisms underlying Notch4/Int3 tumorigenesis, we employed small interfering RNA (siRNA) to knock down c-Kit, PDGFRs and c-Abl alone or in combination and observed the effects on soft agar growth of HC11 cells overexpressing Int 16878155 Mouse
the abl protein malignant transformation The ABL protein possesses the tyrosine kinase activity, which is deregulated in the BCR-ABL protein, leading to the cascade of further pathological processes in the leukemic cells and causing eventually their malignant transformation. 11852587 Human
v-abl fibrosarcoma Exogenous ALA induced the accumulation of substantial concentrations of PpIX in fibrosarcoma cells, and in immortalized fibroblasts transfected with the oncogene c-myc, IGF-1 receptor, IGF-1 and its receptor, v-fos, v-raf, v-Ki-ras, v-abl, or polyomavirus 10360643 Human
v-abl malignant transformation Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. 16709843 Human
c-abl solid tumors There are many reports about c-Abl function in hematopoietic cells, but few are concerned with solid tumors. 10889926 Human
c-abl primary tumor Statistical analyses revealed that c-Abl expression was significantly associated with T-category (p = 0.011), sex (p = 0.014), and differentiation (p = 0.007), but no significant difference was observed with N-category, age, primary tumor region, or the o 10889926 Human
c-abl leukemogenesis These results demonstrate that dimerization alone is sufficient to activate the Abl kinase and provide a method to regulate conditionally c-Abl activity that will be useful for studying the normal physiological role of c-Abl and the mechanism of transform 11320088 Human
c-abl necrosis The results also demonstrate that c-Abl is necessary for ROS-induced depletion of ATP and the activation of a necrosis-like cell death. 11350980 Human
c-abl tumor-specific antigen BACKGROUND: In patients with chronic myelocytic leukemia (CML), the breakpoint cluster region and fusion between the BCR and the c-ABL genes (BCR-ABL) oncogen product is a potential tumor-specific antigen. 11374415 Human
c-abl leukemogenesis Kinase activity, transformation, and leukemogenesis by Bcr-Abl are greatly impaired by mutations of the Bcr coiled-coil domain that disrupt oligomerization, but restored by an SH3 point mutation that blocks ligand binding or a complementary mutation at th 12887890 Human
c-abl small cell lung cancer Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. 16410245 Human
c-abl colorectal cancer c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. 16505115 Human
c-abl cll Conversely, CLL cells transduced with an imatinib-resistant c-Abl mutant could be induced by CD154 to express p73 and Bid even when treated with imatinib. 16741250 Human
c-abl hnscc METHODS: Western blot analysis and immunofluorescence were used to examine the expression of the tyrosine kinases that are known targets of Gleevec, including c-kit, c-Abl, and platelet-derived growth factor receptor, on the cell lines, and immunohistoche 16885745 Human
c-abl glioma Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells. 17126298 Human
p150 metastasis In addition, patients with regional lymph-node metastasis and high p150 expression survived longer than those with regional lymph-node metastasis and lower p150 expression (p < 0.0066). 10096238 Human
abl1 chronic myeloid leukemia (cml) The objective of this study was to characterize the ABL1-BCR fusion gene in 76 BCR-ABL1-positive chronic myeloid leukemia (CML) patients regarding expression as well as genomic status, to assess the frequency of ABL1-BCR gene deletion in these patients, w 11979553 Human
abl1 cml The objective of this study was to characterize the ABL1-BCR fusion gene in 76 BCR-ABL1-positive chronic myeloid leukemia (CML) patients regarding expression as well as genomic status, to assess the frequency of ABL1-BCR gene deletion in these patients, w 11979553 Human
abl1 myeloid metaplasia Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 myelodysplastic syndromes Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 myelofibrosis Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 polycythemia vera Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 essential thrombocythemia Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 mpd Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 myeloproliferative disorders Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metapl 16321848 Human
abl1 mpd This long-sought common mutation in BCR/ABL1-negative MPD raises many provocative biological and clinical questions, and demands re-evaluation of prevailing diagnostic algorithms for erythrocytosis and thrombocytosis. 16321848 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.